Key result
Roux-en-Y gastric bypass shows similar 5.5-year health expenditures to sleeve gastrectomy in diabetes.
Why the study?
It was unclear whether long-term health expenditures differ between Roux-en-Y gastric bypass and sleeve gastrectomy in patients with diabetes.
Does Roux-en-Y gastric bypass compared to sleeve gastrectomy reduce long-term health expenditures in patients with diabetes?
Cohort (n=3,510)
Does Roux-en-Y gastric bypass compared to sleeve gastrectomy reduce long-term health expenditures in patients with diabetes?
Effect estimate: Difference -$217.02 (95% CI -671.29 to 201.96)
Absolute Event Rate: 2441.13% vs 2658.15%
In patients with diabetes, both RYGB and SG lead to substantial reductions in long-term health expenditures, with no significant difference between the two procedures after the first 6 months.
Similar expenditures after RYGB or SG; leaves open whether procedure choice affects long-term costs in diabetes.
BACKGROUND: Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) differ in their effects on body weight and risk for reoperation. However, it is unclear whether long-term health expenditures differ by procedure type in patients with diabetes. OBJECTIVE: To compare health expenditures 3 years before and 5.5 years after bariatric surgery between patients with diabetes undergoing RYGB versus SG. DESIGN: Retrospective cohort study using target trial emulation principles. SETTING: Integrated health system. PATIENTS: = 3510) from 2012 to 2019. MEASUREMENTS: Total, inpatient, outpatient, and medication expenditures. RESULTS: , and average age was 50 years. Expenditures per 6-month period decreased by about 30% for both groups, from $4039.06 (95% CI, $3770.88 to $4326.31) 3 years before to $2441.13 (CI, $2151.07 to $2770.30) 5.5 years after RYGB and from $3918.37 (CI, $3658.75 to $4196.40) 3 years before to $2658.15 (CI, $2279.17 to $3100.16) 5.5 years after SG. Total expenditures after surgery did not differ between groups through 5.5 years (difference at 5.5 years, -$217.02 [CI, -$671.29 to $201.96]) except for the first 6 months, when expenditures were transiently higher in the RYGB group (difference, $564.32 [CI, $232.60 to $895.20]), driven by a higher inpatient admission rate. Otherwise, postsurgical outpatient and medication expenditures did not appear to differ between RYGB and SG. LIMITATION: Unobserved confounding. CONCLUSION: Overall expenditures decreased substantially in the postsurgical period, primarily due to reductions in pharmacy expenditures, with no differences between RYGB and SG except in the first 6 months after surgery. PRIMARY FUNDING SOURCE: National Institute of Diabetes and Digestive and Kidney Diseases.
No takes yet. Share an insight, caveat, or question.
Maciejewski et al. (2025) conducted a cohort in Diabetes (n=3,510). Roux-en-Y gastric bypass (RYGB) vs. Sleeve gastrectomy (SG) was evaluated on Total health expenditures at 5.5 years (Difference -$217.02, 95% CI -671.29 to 201.96). Roux-en-Y gastric bypass and sleeve gastrectomy resulted in similar total health expenditures at 5.5 years in patients with diabetes (difference -$217.02; 95% CI, -$671.29 to $201.96).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: